- Home
- TRGP vs TAK Comparison
TRGP vs TAK Comparison
Compare TRGP & TAK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | TRGP | TAK |
|---|---|---|
| Founded | 2005 | 1781 |
| Country | United States | Japan |
| Employees | N/A | 47455 |
| Industry | Natural Gas Distribution | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 57.7B | 52.4B |
| IPO Year | 2010 | N/A |
Fundamental Metrics
Financial Performance| Metric | TRGP | TAK |
|---|---|---|
| Price | $277.52 | $16.60 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 14 | 0 |
| Target Price | ★ $257.29 | N/A |
| AVG Volume (30 Days) | 1.3M | ★ 2.7M |
| Earning Date | 05-07-2026 | 05-13-2026 |
| Dividend Yield | 2.00% | ★ 3.24% |
| EPS Growth | ★ 47.91 | N/A |
| EPS | ★ 2.21 | N/A |
| Revenue | ★ $17,028,300,000.00 | N/A |
| Revenue This Year | $30.33 | $0.16 |
| Revenue Next Year | $6.55 | $1.22 |
| P/E Ratio | $125.60 | ★ $41.25 |
| Revenue Growth | ★ 3.95 | N/A |
| 52 Week Low | $144.14 | $12.99 |
| 52 Week High | $280.00 | $18.90 |
Technical Indicators
Market Signals| Indicator | TRGP | TAK |
|---|---|---|
| Relative Strength Index (RSI) | 59.86 | 58.77 |
| Support Level | $253.39 | $15.88 |
| Resistance Level | $278.13 | $16.92 |
| Average True Range (ATR) | 7.41 | 0.22 |
| MACD | 0.83 | 0.14 |
| Stochastic Oscillator | 92.61 | 69.94 |
Price Performance
Historical ComparisonAbout TRGP Targa Resources Inc.
Targa Resources Corp is a midstream firm that mainly operates gathering and processing assets with substantial positions in the Permian, Stack, Scoop, and Bakken plays. It has fractionation capacity at Mont Belvieu and operates a liquefied petroleum gas export terminal. The Grand Prix natural gas liquids pipeline is another important asset. It has two operating segments: Gathering and Processing, and, Logistics and Transportation (also referred to as the Downstream Business).
About TAK Takeda Pharmaceutical Company Limited (each representing 1/2 of a share of)
Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4.5 trillion in fiscal 2025. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with about 50% from the US, 10% from Japan, 25% from Europe, and 15% from Canada.